Abstract: The active multidrug efflux pump (EP) has been described as one of the mechanisms involved in the natural drug resistance of bacteria, such as mycobacteria. As a result, the development of efflux pumps inhibitors (EPIs) is an important topic. In this study, a checkerboard synergy assay indicated that farnesol both decreased the minimum inhibitory concentration (MIC) of ethidium bromide (EtBr) 8-fold against Mycobacterium smegmatis (M. smegmatis) mc2155 ATCC 700084 when incorporated at a concentration of 32 μg/mL (FICI = 0.625) and decreased MIC 4-fold at 16 μg/mL (FICI = 0.375). Farnesol also showed synergism when combined with rifampicin. A real-time 96-well plate fluorometric method was used to assess the ability of farnesol to inhibit EPs in comparison withfour positive EPIs: chlorpromazine, reserpine, verapamil, and carbonyl cyanide m-chlorophenylhydrazone (CCCP). Farnesol significantly enhanced the accumulation of EtBr and decreased the efflux of EtBr in M. smegmatis; these results suggest that farnesol acts as an inhibitor of mycobacterial efflux pumps.
Keywords: farnesol; inhibitor; efflux pump; Mycobacterium smegmatis
Export to BibTeX
MDPI and ACS Style
Jin, J.; Zhang, J.-Y.; Guo, N.; Sheng, H.; Li, L.; Liang, J.-C.; Wang, X.-L.; Li, Y.; Liu, M.-Y.; Wu, X.-P.; Yu, L. Farnesol, a Potential Efflux Pump Inhibitor in Mycobacterium smegmatis. Molecules 2010, 15, 7750-7762.
Jin J, Zhang J-Y, Guo N, Sheng H, Li L, Liang J-C, Wang X-L, Li Y, Liu M-Y, Wu X-P, Yu L. Farnesol, a Potential Efflux Pump Inhibitor in Mycobacterium smegmatis. Molecules. 2010; 15(11):7750-7762.
Jin, Jing; Zhang, Ji-Yu; Guo, Na; Sheng, Hui; Li, Lei; Liang, Jun-Chao; Wang, Xue-Lin; Li, Yang; Liu, Ming-Yuan; Wu, Xiu-Ping; Yu, Lu. 2010. "Farnesol, a Potential Efflux Pump Inhibitor in Mycobacterium smegmatis." Molecules 15, no. 11: 7750-7762.